Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 6898505, 9 pages
https://doi.org/10.1155/2017/6898505
Research Article

Morita-Baylis-Hillman Adducts Display Anti-Inflammatory Effects by Modulating Inflammatory Mediator Expression in RAW264.7 Cells

1Laboratório de Biotecnologia Celular e Molecular, Departamento de Biotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, Campus I, João Pessoa, PB, Brazil
2Laboratório de Imunofarmacologia, Departamento de Biologia Celular e Molecular, Centro de Biotecnologia, Universidade Federal da Paraíba, Campus I, João Pessoa, PB, Brazil
3Laboratório de Síntese Orgânica Medicinal da Paraíba (LASOM-PB), Departamento de Química, Universidade Federal da Paraíba, Campus I, João Pessoa, PB, Brazil

Correspondence should be addressed to Glaucia V. Faheina-Martins; rb.moc.oohay@aniehafaicualg and Demetrius A. M. Araújo; rb.bpfu.cetoibc@suirtemed

Received 27 January 2017; Revised 19 May 2017; Accepted 5 June 2017; Published 12 July 2017

Academic Editor: Manoj K. Mishra

Copyright © 2017 Glaucia V. Faheina-Martins et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Y. Cao, “Tumor angiogenesis and therapy,” Biomedicine and Pharmacotherapy, vol. 59, pp. 340–343, 2005. View at Google Scholar
  2. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, “Cancer-related inflammation,” Nature, vol. 454, pp. 436–444, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. B. B. Aggarwal, R. V. Vijayalekshmi, and B. Sung, “Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe,” Clinical Cancer Research, vol. 15, pp. 425–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Sethi, M. K. Shanmugam, L. Ramachandran, A. L. Kumar, and V. Tergaonkar, “Multifaceted link between cancer and inflammation,” Bioscience Reports, vol. 32, pp. 1–15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Colotta, P. Allavena, A. Sica, C. Garlanda, and A. Mantovani, “Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability,” Carcinogenesis, vol. 30, pp. 1073–1081, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. B. B. Aggarwal, S. Shishodia, S. K. Sandur, M. K. Pandey, and G. Sethi, “Inflammation and cancer: how hot is the link?” Biochemical Pharmacology, vol. 72, pp. 1605–1616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. B. B. Aggarwal and P. Gehlot, “Inflammation and cancer: how friendly is the relationship for cancer patients?” Current Opinion in Pharmacology, vol. 9, pp. 351–369, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Balkwill and A. Mantovani, “Cancer and inflammation: implications for pharmacology and therapeutics,” Clinical Pharmacology and Therapeutics, vol. 87, pp. 401–406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. D. S. Hong, L. S. Angelo, and R. Kurzrock, “Interleukin-6 and its receptor in cancer: implications for translational therapeutics,” Cancer, vol. 110, pp. 1911–1928, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. W. E. Naugler and M. Karin, “The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer,” Trends in Molecular Medicine, vol. 14, pp. 109–119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. W. W. Lin and M. Karin, “A cytokine-mediated link between innate immunity, inflammation, and cancer,” The Journal of Clinical Investigation, vol. 117, pp. 1175–1183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Landskron, M. D. Fuente, P. Thuwajit, C. Thuwajit, and M. A. Hermoso, “Chronic inflammation and cytokines in the tumor microenvironment,” Journal of Immunology Research, vol. 2014, pp. 1–19, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S.-Y. Kim, J. W. Kang, X. Song et al., “Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells,” Cell Signaling, vol. 25, pp. 961–969, 2013. View at Google Scholar
  14. J. Coward, H. Kulbe, P. Chakravarty et al., “Interleukin-6 as a therapeutic target in human ovarian cancer,” Clinical Cancer Research, vol. 17, pp. 6083–6096, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Kurzrock, P. M. Voorhees, C. Casper et al., “A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease,” Clinical Cancer Research, vol. 19, pp. 3659–3670, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. Y.-Z. Yang, Y.-Z. Tang, and Y.-H. Liu, “Wogonoside displays anti-inflammatory effects through modulating inflammatory mediator expression using RAW264.7 cells,” Journal of Ethnopharmacology, vol. 48, pp. 271–276, 2013. View at Google Scholar
  17. M. Fang, S. Y. Lee, S. M. Park et al., “Anti-inflammatory potential of Phaseolus calcaratus Roxburgh, an oriental medicine, on LPS-stimulated RAW 264.7 macrophages,” Journal of Pharmacy and Pharmacology, vol. 63, pp. 120–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. T. Chan, S. Ogino, and C. S. Fuchs, “Aspirin and the risk of colorectal cancer in relation to the expression of COX-2,” The New England Journal of Medicine, vol. 356, pp. 2131–2142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. L. J. Marnett, “Oxyradicals and DNA damage,” Carcinogenesis, vol. 21, pp. 361–370, 2000. View at Publisher · View at Google Scholar
  20. L. K. Kohn, C. H. Pavam, D. Veronense, F. Coelho, J. E. De Carvalho, and W. P. Almeida, “Antiproliferative effect of Baylis-Hillman adducts and a new phthalide derivative on human tumor cell lines,” European Journal of Medicinal Chemistry, vol. 41, pp. 738–744, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. A. Leite, C. G. L. Junior, F. P. L. Silva, S. C. O. Sousa, M. L. A. A. Vasconcellos, and L. F. Marques-Santos, “Antimitotic activity on sea urchin embryonic cells of seven antiparasitic Morita-Baylis-Hillman adducts: a potential new class of anticancer drugs,” Medicinal Chemistry, vol. 8, pp. 1003–1011, 2012. View at Google Scholar
  22. C. G. Lima-Junior and M. L. A. A. Vasconcellos, “Morita–Baylis–Hillman adducts: biological activities and potentialities to the discovery of new cheaper drugs,” Bioorganic & Medicinal Chemistry, vol. 20, pp. 3954–3971, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. C. G. Lima-Junior, G. V. Faheina-Martins, C. C. Bomfim et al., “Synthesis, cytotoxic activity on leukemia cell lines and quantitative structure-activity relationships (QSAR) studies of Morita-Baylis-Hillman adducts,” Medicinal Chemistry, vol. 8, pp. 602–612, 2016. View at Google Scholar
  24. G. V. Faheina Martins, A. L. Silveira, B. C. Cavalcanti et al., “Antiproliferative effects of lectins from Canavalia ensiformis and Canavalia brasiliensis in human leukemia cell lines,” Toxicology in Vitro, vol. 26, pp. 1161–1169, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Comalada, I. Ballester, E. Bailon et al., “Inhibition of pro-inflammatory markers in primary bone marrow-derived mouse macrophages by naturally occurring flavonoids: analysis of the structure–activity relationship,” Biochemical Pharmacology, vol. 72, pp. 1010–1021, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Nakahira, J. A. Haspel, V. A. K. Rathinam et al., “Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome,” Nature Immunology, vol. 12, pp. 222–230, 2011. View at Google Scholar
  27. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschoop, “A role for mitochondria in NLRP3 inflammasome activation,” Nature, vol. 469, pp. 221–225, 2011. View at Google Scholar
  28. M. Philip, D. A. Rowley, and H. Schreiber, “Inflammation as a tumor promoter in cancer induction,” Seminars in Cancer Biology, vol. 14, pp. 433–439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. S. I. Grivennikov, F. R. Greten, and M. Karin, “Immunity, inflammation, and cancer,” Cell, vol. 140, pp. 883–899, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. C. Bulua, A. Simon, R. Maddipati et al., “Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS),” The Journal of Experimental Medicine, vol. 208, pp. 519–533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. M. J. Toomey, J. F. Murphy, and K. C. Colon, “Cox-2, VEGF and tumor angiogenesis,” The Surgeon, vol. 7, pp. 174–180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. X. Ma, Y. L. Sun, Y. Q. Wang, H. Y. Wu, J. Jin, and X. F. Yu, “Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF,” Oncology Research, vol. 20, pp. 359–368, 2013. View at Google Scholar
  33. J. A. Lust, M. Q. Lacy, S. R. Zeldenrust et al., “Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin1β-induced interleukin 6 production and the myeloma proliferative component,” Mayo Clinic Proceedings, vol. 84, pp. 114–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. J. Jung, J. S. Isaacs, S. Lee, J. Trepel, and L. Neckers, “IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis,” The FASEB Journal, vol. 17, pp. 2115–2117, 2003. View at Publisher · View at Google Scholar
  35. F. R. Paula, S. H. P. Serrano, and L. C. Tavares, “Aspectos mecanísticos da bioatividade e toxicidade de nitrocompostos,” Quim Nova, vol. 32, pp. 1013–1020, 2009. View at Publisher · View at Google Scholar
  36. Z. Qi, F. Yin, L. Lu et al., “Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production,” Inflammation Research, vol. 62, pp. 1–11, 2013. View at Google Scholar